Results 131 to 140 of about 15,564 (249)

Targeting the neonatalFcreceptor (FcRn) to treat autoimmune diseases and maternal‐fetal immune cytopenias

, 2021
Sarah L. Wyckoff, Krystalyn E. Hudson
openalex   +2 more sources

Reduction in Synaptic Vesicle Protein Abundance but Increased Amounts of Nsg2 and Lpcat1 in Cerebral Cortices Without the Endosomal SNARE Proteins Vti1a and Vti1b

PROTEOMICS, Volume 26, Issue 5, Page 86-97, May 2026.
ABSTRACT Absence of the endosomal SNAREs vti1a and vti1b results in perinatal death and severe neuronal phenotypes in mice, while lack of one of these proteins results in minor phenotypes. Proteomic differences were investigated to obtain a deeper insight into processes in which vti1a and vti1b are involved.
Julia Gottschalk, Katharina Kotschnew, Julia Hahn, Thomas Patschkowski, Gabriele von Fischer von Mollard   +4 more
wiley   +1 more source

Functional characterization of DPP4 and FcRn as receptor and coreceptor for classical human astroviruses in Caco-2 cells.

PLoS Pathogens
Classical human astroviruses (HAstV) are a global cause of viral gastroenteritis, particularly in children and immunocompromised individuals. Despite their clinical significance, the biology of HAstV remains poorly understood.
Catalina Aguilera-Flores, María Del Pilar Valencia-Morales, Tomás López, Joaquín Moreno-Contreras, Adam Lentz, Marco A Espinoza, Rebecca M DuBois, Susana López, Carlos F Arias   +8 more
doaj   +1 more source

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties

mAbs
Nipocalimab is a human immunoglobulin G (IgG)1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn) with high specificity and high affinity at both neutral (extracellular) and acidic (intracellular) pH, resulting in the reduction of ...
Nilufer P. Seth, Rui Xu, Matthew DuPrie, Amit Choudhury, Samuel Sihapong, Steven Tyler, James Meador, William Avery, Edward Cochran, Thomas Daly, Julia Brown, Laura Rutitzky, Lynn Markowitz, Sujatha Kumar, Traymon Beavers, Sayak Bhattacharya, Hsin Chen, Viraj Parge, Karen Price, Yang Wang, Siddharth Sukumaran, Yvonne Pao, Katie Abouzahr, Fiona Elwood, Jay Duffner, Sucharita Roy, Pushpa Narayanaswami, Jonathan J. Hubbard, Leona E. Ling   +28 more
doaj   +1 more source

SkinNet: A Deep Learning Framework for Skin Lesion Segmentation

, 2018
There has been a steady increase in the incidence of skin cancer worldwide, with a high rate of mortality. Early detection and segmentation of skin lesions are crucial for timely diagnosis and treatment, necessary to improve the survival rate of patients.
Maier, Andreas, Ravikumar, Nishant, Vesal, Sulaiman   +2 more
core   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn

mAbs
Monoclonal antibodies (mAbs) as therapeutics necessitate favorable pharmacokinetic properties, including extended serum half-life, achieved through pH-dependent binding to the neonatal Fc receptor (FcRn).
Johannes Reusch, Jan Terje Andersen, Ulrich Rant, Tilman Schlothauer   +3 more
doaj   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 688-699, April 2026.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Improving drug-like properties of protein therapeutics through peptide extensions that interact with the Fc fragment of IgG receptor transporter-α (FCGRT; FCRN) [PDF]

, 2012

openalex   +1 more source

Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 714-723, April 2026.
ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein, Haoqi Sun, Sophie Lehnerer, Lea Gerischer, Maximilian Mönch, Christian Meisel, Andreas Meisel, Pushpa Narayanaswami   +7 more
wiley   +1 more source